Recent 8-K filings for RMTI

• May 8, 2026, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  Rockwell Medical receives Nasdaq delisting notice for bid price below $1.00

  Notice issued May 8, 2026 for failing to meet $1.00 minimum bid price over 30 consecutive business days.

• May 7, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Rockwell Medical Q1 net sales $17.3M (-8% YoY); guides FY26 gross margin 18-22%

  Net sales $17.3M, down 8% from $18.9M; net loss $1.6M vs $1.5M in prior year.

• March 26, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Rockwell Medical Q4 2025 net sales $18.3M, gross margin 21% (up from 15%), full-year Adj. EBITDA $0.3M

  Q4 2025 net sales $18.3M (vs $24.7M Q4 2024); full-year net sales $69.3M (vs $101.5M) driven by reduced customer purchase volumes.

• January 20, 2026, 6:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  Rockwell Medical prelim Q4 sales ~$18.6M; cash flow positive $2.3M

  Preliminary Q4 2025 net sales ~$18.6M; full-year 2025 ~$69.5M (audit pending).

• January 5, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01

  Rockwell Medical extends DaVita supply agreement to Dec 2026 with price hike

  Second Amendment extends Products Purchase Agreement through Dec 31, 2026.

• November 12, 2025, 6:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Rockwell Medical Q3 net sales fall 44% to $15.9M; net loss of $1.8M vs profit year ago

  Net sales $15.9M, down 44% YoY due to largest customer transitioning to another supplier.

• August 14, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Rockwell Medical Q2 2025 revenue drops 38% to $16.1M, net loss of $1.5M

  Net sales $16.1M, down 38% YoY, driven by loss of largest customer; gross margin 16% in line with guidance.

• May 12, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Rockwell Medical Q1 net sales $18.9M (-17% YoY); net loss improves to $1.5M

  Net sales fell 17% to $18.9M, driven by largest customer transitioning to another supplier.

• March 20, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Rockwell Medical Reports Record Net Sales and First Full-Year Adjusted EBITDA Profitability in 2024

  Record net sales of $101.5M in 2024, a 21% increase over 2023.

• November 12, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Rockwell Medical Q3 2024 net income $1.7M, raises guidance; largest customer revenue expected to decline $31-38M in 2025

  Net product sales $28.3M (+31% YoY); gross profit $6.2M (+183%); gross margin 22% vs 9%.

• August 8, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Rockwell Medical Q2 net sales $25.8M (+43% YoY), net income $0.3M, raises FY 2024 guidance

  Net sales $25.8M (+43% YoY); gross profit $4.6M (+341%); gross margin expanded to 18% from 6%.

• July 15, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 7.01item 9.01

  Rockwell Medical amends asset purchase deal with Evoqua; affirms 2024 gross margin guidance of 14-16%

  Amendment reduces First Deferred Payment by $322,260 to $2,177,740, payable in four quarterly installments through April 2025.

• May 14, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Rockwell Medical Q1 record sales $22.7M (+15% YoY); raises 2024 guidance across all metrics

  Q1 net sales $22.7M (record), up 15% YoY; ex-deferred revenue, up 25%. Gross profit $3.1M (+18% YoY).

• March 21, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Rockwell Medical posts record 2023 net sales of $83.6M; achieves first-ever adjusted EBITDA profit in Q4

  Q4 2023 net sales $22.1M (+14% YoY); Q4 adjusted EBITDA $0.5M vs ($0.6M) in Q4 2022, first positive quarter in company history.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.50 · Most common event earnings

7 positive 4 negative 18 neutral

source · RMTI on sec.gov